1. Moderator's note. If you talk about someone on the board, your post will be removed. We are at 10 removals on this page. That is up slightly. You are wasting your time when you post in that manner. Moderator's note.
2. I had time to read the Jason article. The RP study was reported in the Spring of 2012. Interesting. AND no followup studies have yet been done.
3. Jason notes that Big Pharma will be needed to study MANF for PD. We knew that, but it bears repeating.
4. As some doubted, the Lympro BD study is ongoing with data back in the next few months. If the study is positive, AMBS will most certainly see money from BD or some other company.
5. The key to this is that Pharma could write off RP research immediately due to its orphan status. That would not happen with PD since it is more common than 200000.
6. The key to this RP announcement to me is that the study happened in 2011 and 2012, and was reported in May of 2012. The AMBS release notes that the study was reported in 2012. It does mention the month. No wonder why the stock did not move. Amazing. One other thing, the study was an abstract. IOW it was not accepted for publication by a major opthamologic publication. While not getting accepted is the norm, it speaks against the process in general.
7. The pps is probably now in an uptrend. For a brief period there are higher lows and higher highs. WHEN and if the pps STAYS above teh 50 day MA, then we will have an uptrend.
8. However, this RP release is yet another PR move, accompanied by multiple sources of pumping. In the past this indicated that a HUGE dilution was coming. Oh well. With all of this, and the LATE SEC filing, I would EXPECT a HUGE dilution ahead.
News 
Market Data 
Discover 
AI
